3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
16
Neoplasms
6
Prostate Cancer Metastatic
4
Solid Cancer
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer, MCRPC
1
Malignant Solid Tumor - Malignant Nervous System Neoplasm
1
Castrate-Resistant Prostate Cancer
1
Advanced Solid Tumor
1
Interventions
enzalutamide
14
Docetaxel
7
radium Ra 223 dichloride
6
Abiraterone Acetate
6
Prednisone
5
darolutamide
4
abiraterone
3
olaparib
2
niraparib
2
atezolizumab
2
apalutamide
2
zimberelimab
1
xentuzumab
1
tasquinimod
1
sacituzumab govitecan
1
sabizabulin
1
quemliclustat
1
ipatasertib
1
ibrutinib
1
gedatolisib
1
gallium 68 PSMA-11
1
fludrocortisone acetate
1
cabazitaxel
1
Rosuvastatin Calcium
1
Radium-223
1
Pluvicto
1
Pioglitazone
1
Nivolumab
1
JNJ-64619178
1
JNJ-64264681
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms, Castration-Resistant
×
cabazitaxel
×
Clear all
NCT06353386
2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
220 enrolled